< Back to previous page
Researcher
Ann Janssens
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Oct 2013 → Today
Publications
1 - 10 of 181
- Pseudo-acute kidney injury secondary to tepotinib(2023)
Authors: Ann Janssens
Pages: 760 - 761 - Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer(2023)
Authors: Ann Janssens
Pages: 635 - 646 - [18F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma(2023)
Authors: Vibeke Vergote, Gregor Verhoef, Ann Janssens, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, Christophe Deroose
Pages: 161 - 170 - The Limits and Possibilities of Cause of Death Categorisation for Understanding Late Nineteenth Century Mortality(2022)
Authors: Ann Janssens
Pages: 1053 - 1063 - Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.(2022)
Authors: Ann Janssens
Pages: 133 - 143 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study(2022)
Authors: Ann Janssens
Pages: 2333 - 2337 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL(2022)
Authors: Ann Janssens
Pages: 2772 - 2775 - Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)(2022)
Authors: Ann Janssens
- High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations(2022)
Authors: Ann Janssens
- Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial(2022)
Authors: Ann Janssens